# Gene Screening in High-Throughput Right-Censored Lung Cancer Data

^{1}

^{2}

^{3}

^{4}

^{*}

## Abstract

**:**

## 1. Introduction

## 2. Materials and Methods

#### 2.1. Data Description

#### 2.2. Sure Independence Screening for Right-Censored Data

#### 2.3. The Screening Index

#### 2.4. The Sreening Algorithm

- (1)
- Estimate the survival function by the Kaplan–Meier estimator as$${\widehat{F}}_{T}\left(t\right):=1-\prod _{i=1}^{n}{\left(1-\frac{1}{{\sum}_{l=1}^{n}I\{{Y}_{l}\ge {Y}_{i}\}}\right)}^{{\delta}_{i}I\{{Y}_{i}\le t\}}$$
- (2)
- Treat ${\{{\widehat{F}}_{{X}_{j}}\left({X}_{ij}\right),{\widehat{F}}_{T}\left({Y}_{i}\right)\}}_{i=1}^{n}$ as the observed data of $({U}_{{X}_{j}},{U}_{T})$ and compute the sample correlation ${\widehat{w}}_{j}:={\rho}_{K,G,n}\left({U}_{T}\right|{U}_{{X}_{j}})$ for $j=1,...,p$.
- (3)
- Let $\widehat{\mathcal{A}}:=\{1\le j\le p:{\widehat{w}}_{j}\phantom{\rule{3.33333pt}{0ex}}\mathrm{is}\phantom{\rule{4.pt}{0ex}}\mathrm{among}\phantom{\rule{4.pt}{0ex}}\mathrm{the}\phantom{\rule{4.pt}{0ex}}\mathrm{first}\phantom{\rule{3.33333pt}{0ex}}d\phantom{\rule{3.33333pt}{0ex}}\mathrm{largest}\phantom{\rule{4.pt}{0ex}}\mathrm{of}\phantom{\rule{4.pt}{0ex}}\mathrm{all}\}$.

`R`code to implement the proposed algorithm is available at https://github.com/cke23/GeneScreeningDemo1 (accessed on 30 September 2022).

#### 2.5. Application

## 3. Results

## 4. Discussion

## 5. Conclusions

## Author Contributions

## Funding

## Institutional Review Board Statement

## Informed Consent Statement

## Data Availability Statement

## Conflicts of Interest

## References

- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.
**2021**, 71, 209–249. [Google Scholar] [CrossRef] [PubMed] - Custodio, A.; Méndez, M.; Provencio, M. Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. Cancer Treat. Rev.
**2012**, 38, 36–53. [Google Scholar] [CrossRef] - The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature
**2012**, 489, 519–525. [Google Scholar] [CrossRef] [Green Version] - Suda, K.; Mitsudomi, T. Successes and limitations of targeted cancer therapy in lung cancer. Successes Limitations Target. Cancer Ther.
**2014**, 41, 62–77. [Google Scholar] - Lee, Y.T.; Tan, Y.J.; Oon, C.E. Molecular targeted therapy: Treating cancer with specificity. Eur. J. Pharmacol.
**2018**, 834, 188–196. [Google Scholar] [CrossRef] [PubMed] - Pi, L.; Halabi, S. Combined performance of screening and variable selection methods in ultra-high dimensional data in predicting time-to-event outcomes. Diagn. Progn. Res.
**2018**, 2, 21. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Chandrashekar, G.; Sahin, F. A survey on feature selection methods. Comput. Electr. Eng.
**2014**, 40, 16–28. [Google Scholar] [CrossRef] - Larsen, J.E.; Pavey, S.J.; Passmore, L.H.; Bowman, R.; Clarke, B.E.; Hayward, N.K.; Fong, K.M. Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis
**2007**, 28, 760–766. [Google Scholar] [CrossRef] [Green Version] - Skrzypski, M.; Jassem, E.; Taron, M.; Sanchez, J.J.; Mendez, P.; Rzyman, W.; Gulida, G.; Raz, D.; Jablons, D.; Provencio, M.; et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin. Cancer Res.
**2008**, 14, 4794–4799. [Google Scholar] [CrossRef] [Green Version] - Xu, F.; Lin, H.; He, P.; He, L.; Chen, J.; Lin, L.; Chen, Y. A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma. Oncoimmunology
**2020**, 9, 1731943. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Qu, H.Q.; Tien, M.; Polychronakos, C. Statistical significance in genetic association studies. Clin. Investig. Med. Med. Clin. Exp.
**2010**, 33, E266. [Google Scholar] [CrossRef] [PubMed] - Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.)
**1995**, 57, 289–300. [Google Scholar] [CrossRef] - Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. Ser. B (Methodol.)
**1996**, 58, 267–288. [Google Scholar] [CrossRef] - Chen, J.W.; Dhahbi, J. Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods. Sci. Rep.
**2021**, 11, 13323. [Google Scholar] [CrossRef] [PubMed] - Fan, J.; Lv, J. Sure independence screening for ultrahigh dimensional feature space. J. R. Stat. Soc. Ser. B (Stat. Methodol.)
**2008**, 70, 849–911. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Li, R.; Zhong, W.; Zhu, L. Feature screening via distance correlation learning. J. Am. Stat. Assoc.
**2012**, 107, 1129–1139. [Google Scholar] [CrossRef] [Green Version] - Balasubramanian, K.; Sriperumbudur, B.; Lebanon, G. Ultrahigh Dimensional Feature Screening via RKHS Embeddings; Artificial Intelligence and Statistics: Scottsdale, AZ, USA, 2013; pp. 126–134. [Google Scholar]
- Mai, Q.; Zou, H. The fused Kolmogorov filter: A nonparametric model-free screening method. Ann. Stat.
**2015**, 43, 1471–1497. [Google Scholar] [CrossRef] [Green Version] - Cui, H.; Li, R.; Zhong, W. Model-free feature screening for ultrahigh dimensional discriminant analysis. J. Am. Stat. Assoc.
**2015**, 110, 630–641. [Google Scholar] [CrossRef] [PubMed] - Beyene, J.; Atenafu, E.G.; Hamid, J.S.; To, T.; Sung, L. Determining relative importance of variables in developing and validating predictive models. BMC Med. Res. Methodol.
**2009**, 9, 64. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Heinzel, A.; Perco, P.; Mayer, G.; Oberbauer, R.; Lukas, A.; Mayer, B. From molecular signatures to predictive biomarkers: Modeling disease pathophysiology and drug mechanism of action. Front. Cell Dev. Biol.
**2014**, 2, 37. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Fan, J.; Feng, Y.; Wu, Y. High-dimensional variable selection for Cox’s proportional hazards model. In Borrowing Strength: Theory Powering Applications—A Festschrift for Lawrence D. Brown; Institute of Mathematical Statistics: Hayward, CA, USA, 2010; pp. 70–86. [Google Scholar]
- Zhao, S.D.; Li, Y. Principled sure independence screening for Cox models with ultra-high-dimensional covariates. J. Multivar. Anal.
**2012**, 105, 397–411. [Google Scholar] [CrossRef] [PubMed] - Gorst-Rasmussen, A.; Scheike, T. Independent screening for single-index hazard rate models with ultrahigh dimensional features. J. R. Stat. Soc.: Ser. B (Stat. Methodol.)
**2013**, 75, 217–245. [Google Scholar] [CrossRef] [Green Version] - Iuliano, A.; Occhipinti, A.; Angelini, C.; De Feis, I.; Liò, P. Combining pathway identification and breast cancer survival prediction via screening-network methods. Front. Genet.
**2018**, 9, 206. [Google Scholar] [CrossRef] - Tschodu, D.; Ulm, B.; Bendrat, K.; Lippoldt, J.; Gottheil, P.; Käs, J.A.; Niendorf, A. Comparative analysis of molecular signatures reveals a hybrid approach in breast cancer: Combining the Nottingham Prognostic Index with gene expressions into a hybrid signature. PLOS ONE
**2022**, 17, e0261035. [Google Scholar] [CrossRef] - Zhang, R.; Chen, C.; Dong, X.; Shen, S.; Lai, L.; He, J.; You, D.; Lin, L.; Zhu, Y.; Huang, H.; et al. Independent validation of early-stage non-small cell lung cancer prognostic scores incorporating epigenetic and transcriptional biomarkers with gene-gene interactions and main effects. Chest
**2020**, 158, 808–819. [Google Scholar] [CrossRef] [PubMed] - Zhao, K.; Li, Z.; Tian, H. Twenty-gene-based prognostic model predicts lung adenocarcinoma survival. Oncotargets Ther.
**2018**, 11, 3415. [Google Scholar] [CrossRef] [Green Version] - He, X.; Wang, L.; Hong, H.G. Quantile-adaptive model-free variable screening for high-dimensional heterogeneous data. Ann. Stat.
**2013**, 41, 342–369. [Google Scholar] [CrossRef] - Song, R.; Lu, W.; Ma, S.; Jessie Jeng, X. Censored rank independence screening for high-dimensional survival data. Biometrika
**2014**, 101, 799–814. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Li, J.; Zheng, Q.; Peng, L.; Huang, Z. Survival impact index and ultrahigh-dimensional model-free screening with survival outcomes. Biometrics
**2016**, 72, 1145–1154. [Google Scholar] [CrossRef] [Green Version] - Hong, H.G.; Chen, X.; Christiani, D.C.; Li, Y. Integrated powered density: Screening ultrahigh dimensional covariates with survival outcomes. Biometrics
**2018**, 74, 421–429. [Google Scholar] [CrossRef] [PubMed] - Chen, X.; Chen, X.; Wang, H. Robust feature screening for ultra-high dimensional right censored data via distance correlation. Comput. Stat. Data Anal.
**2018**, 119, 118–138. [Google Scholar] [CrossRef] - Hong, H.G.; Li, Y. Feature selection of ultrahigh-dimensional covariates with survival outcomes: A selective review. Appl. Math.
**2017**, 32, 379–396. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Ke, C.; Yin, X. Expected Conditional Characteristic Function-based Measures for Testing Independence. J. Am. Stat. Assoc.
**2020**, 115, 985–996. [Google Scholar] [CrossRef] - Botling, J.; Edlund, K.; Lohr, M.; Hellwig, B.; Holmberg, L.; Lambe, M.; Berglund, A.; Ekman, S.; Bergqvist, M.; Pontén, F.; et al. Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray ValidationGene Expression–Based Biomarker Discovery in NSCLC. Clin. Cancer Res.
**2013**, 19, 194–204. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Rousseaux, S.; Debernardi, A.; Jacquiau, B.; Vitte, A.L.; Vesin, A.; Nagy-Mignotte, H.; Moro-Sibilot, D.; Brichon, P.Y.; Lantuejoul, S.; Hainaut, P.; et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci. Transl. Med.
**2013**, 5, 186ra66. [Google Scholar] [CrossRef] [Green Version] - Fukumizu, K.; Gretton, A.; Lanckriet, G.R.; Schölkopf, B.; Sriperumbudur, B.K. Kernel Choice and Classifiability for RKHS Embeddings of Probability Distributions. In Advances in Neural Information Processing Systems 22; Bengio, Y., Schuurmans, D., Lafferty, J.D., Williams, C.K.I., Culotta, A., Eds.; Curran Associates, Inc.: Red Hook, NY, USA, 2009; pp. 1750–1758. [Google Scholar]
- Sejdinovic, D.; Sriperumbudur, B.; Gretton, A.; Fukumizu, K. Equivalence of distance-based and RKHS-based statistics in hypothesis testing. Ann. Stat.
**2013**, 41, 2263–2291. [Google Scholar] [CrossRef] - Silverman, B.W. Density Estimation for Statistics and Data Analysis; CRC Press: Boca Raton, FL, USA, 1986. [Google Scholar]
- Ren, J.; Du, Y.; Li, S.; Ma, S.; Jiang, Y.; Wu, C. Robust network-based regularization and variable selection for high-dimensional genomic data in cancer prognosis. Genet. Epidemiol.
**2019**, 43, 276–291. [Google Scholar] [CrossRef] - Dwight, T.; Na, U.; Kim, E.; Zhu, Y.; Richardson, A.L.; Robinson, B.G.; Tucker, K.M.; Gill, A.J.; Benn, D.E.; Clifton-Bligh, R.J.; et al. Analysis of SDHAF3 in familial and sporadic pheochromocytoma and paraganglioma. BMC Cancer
**2017**, 17, 497. [Google Scholar] [CrossRef] [Green Version] - Moreno, C.; Santos, R.M.; Burns, R.; Zhang, W.C. Succinate Dehydrogenase and Ribonucleic Acid Networks in Cancer and Other Diseases. Cancers
**2020**, 12, 3237. [Google Scholar] [CrossRef] - Tseng, P.L.; Wu, W.H.; Hu, T.H.; Chen, C.W.; Cheng, H.C.; Li, C.F.; Tsai, W.H.; Tsai, H.J.; Hsieh, M.C.; Chuang, J.H.; et al. Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect. Sci. Rep.
**2018**, 8, 3081. [Google Scholar] [CrossRef] [Green Version] - Guo, X.; Li, D.; Wu, Y.; Chen, Y.; Zhou, X.; Wang, X.; Huang, X.; Li, X.; Yang, H.; Xing, J. Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer. Lung Cancer
**2015**, 87, 162–168. [Google Scholar] [CrossRef] [PubMed] - Campbell, R.; Chong, G.; Hawkes, E.A. Novel indications for Bruton’s tyrosine kinase inhibitors, beyond hematological malignancies. J. Clin. Med.
**2018**, 7, 62. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Albano, F.; Chiurazzi, F.; Mimmi, S.; Vecchio, E.; Pastore, A.; Cimmino, C.; Frieri, C.; Iaccino, E.; Pisano, A.; Golino, G.; et al. The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis. Cell Death Dis.
**2018**, 9, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Tian, S. Identification of monotonically differentially expressed genes for non-small cell lung cancer. BMC Bioinform.
**2019**, 20, 177. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Mardakheh, F.K.; Self, A.; Marshall, C.J. RHO binding to FAM65A regulates Golgi reorientation during cell migration. J. Cell Sci.
**2016**, 129, 4466–4479. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Ridley, A. RhoA, RhoB and RhoC have different roles in cancer cell migration. J. Microsc.
**2013**, 251, 242–249. [Google Scholar] [CrossRef] - Howrylak, J.A.; Moll, M.; Weiss, S.T.; Raby, B.A.; Wu, W.; Xing, E.P. Gene expression profiling of asthma phenotypes demonstrates molecular signatures of atopy and asthma control. J. Allergy Clin. Immunol.
**2016**, 137, 1390–1397. [Google Scholar] [CrossRef] [Green Version] - Kachuri, L.; Johansson, M.; Rashkin, S.R.; Graff, R.E.; Bossé, Y.; Manem, V.; Caporaso, N.E.; Landi, M.T.; Christiani, D.C.; Vineis, P.; et al. Immune-mediated genetic pathways resulting in pulmonary function impairment increase lung cancer susceptibility. Nat. Commun.
**2020**, 11, 27. [Google Scholar] [CrossRef] [Green Version] - Poteryaev, D.; Datta, S.; Ackema, K.; Zerial, M.; Spang, A. Identification of the switch in early-to-late endosome transition. Cell
**2010**, 141, 497–508. [Google Scholar] [CrossRef] [Green Version] - Shao, X.; Liu, Y.; Yu, Q.; Ding, Z.; Qian, W.; Zhang, L.; Zhang, J.; Jiang, N.; Gui, L.; Xu, Z.; et al. Numb regulates vesicular docking for homotypic fusion of early endosomes via membrane recruitment of Mon1b. Cell Res.
**2016**, 26, 593–612. [Google Scholar] [CrossRef] [Green Version] - Jiang, L.; Qian, J.; Yang, Y.; Fan, Y. Knockdown of MON1B Exerts Anti-Tumor Effects in Colon Cancer In Vitro. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.
**2018**, 24, 7710–7718. [Google Scholar] [CrossRef] [PubMed] - Xuan, C.; Wang, Q.; Han, X.; Duan, Y.; Li, L.; Shi, L.; Wang, Y.; Shan, L.; Yao, Z.; Shang, Y. RBB, a novel transcription repressor, represses the transcription of HDM2 oncogene. Oncogene
**2013**, 32, 3711–3721. [Google Scholar] [CrossRef] [PubMed] - Kheder, E.S.; Hong, D.S. Emerging Targeted Therapy for Tumors with NTRK Fusion ProteinsNovel Targeted Therapy for NTRK-Rearranged Tumors. Clin. Cancer Res.
**2018**, 24, 5807–5814. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Jones, D.T.; Hutter, B.; Jäger, N.; Korshunov, A.; Kool, M.; Warnatz, H.J.; Zichner, T.; Lambert, S.R.; Ryzhova, M.; Quang, D.A.K.; et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet.
**2013**, 45, 927–932. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Amatu, A.; Sartore-Bianchi, A.; Siena, S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open
**2016**, 1, e000023. [Google Scholar] [CrossRef] [Green Version] - Zhang, D.; Xi, Y.; Coccimiglio, M.L.; Mennigen, J.A.; Jonz, M.G.; Ekker, M.; Trudeau, V.L. Functional prediction and physiological characterization of a novel short trans-membrane protein 1 as a subunit of mitochondrial respiratory complexes. Physiol. Genom.
**2012**, 44, 1133–1140. [Google Scholar] [CrossRef] [Green Version] - Mullin, B.H.; Zhu, K.; Brown, S.J.; Mullin, S.; Tickner, J.; Pavlos, N.J.; Dudbridge, F.; Xu, J.; Walsh, J.P.; Wilson, S.G. Genetic regulatory mechanisms in human osteoclasts suggest a role for the STMP1 and DCSTAMP genes in Paget’s disease of bone. Sci. Rep.
**2019**, 9, 1052. [Google Scholar] [CrossRef] [Green Version] - Feingold, E.; Pachter, L. The ENCODE (ENCyclopedia of DNA elements) project. Science
**2004**, 306, 636–640. [Google Scholar] - Consortium, E.P. A user’s guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol.
**2011**, 9, e1001046. [Google Scholar] - Rouillard, A.D.; Gundersen, G.W.; Fernandez, N.F.; Wang, Z.; Monteiro, C.D.; McDermott, M.G.; Ma’ayan, A. The harmonizome: A collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database
**2016**, 2016, baw100. [Google Scholar] [CrossRef] - Trimarchi, J.M.; Lees, J.A. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol.
**2002**, 3, 11–20. [Google Scholar] [CrossRef] [PubMed] - Kar, A.; Gutierrez-Hartmann, A. Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Crit. Rev. Biochem. Mol. Biol.
**2013**, 48, 522–543. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell
**2011**, 144, 646–674. [Google Scholar] [CrossRef] [PubMed]

**Figure 2.**Kaplan–Meier curves of overall survival for test (TCGA) and validation (GEO) cohorts varying with the risk level determined by the four competing models. p-values were obtained from the log-rank tests contrasting the two risk groups.

**Figure 3.**Kaplan–Meier curves of disease-free survival for test (TCGA) and validation (GEO) cohorts varying with the risk level determined by the four competing models. p-values were obtained from the log-rank tests contrasting the two risk groups.

**Figure 4.**ROC curves of overall survival predicted by the four competing models on the external validation data.

Variables | Frequency (Percent) |
---|---|

Age | |

Less than 50 | 15 (3.2%) |

50–59 | 67 (14.2%) |

60–69 | 178 (37.6%) |

70–79 | 186 (39.3%) |

80 or greater | 27 (5.7%) |

Gender | |

Female | 125 (26.4%) |

Male | 348 (73.6%) |

Smoking History | |

Current reformed smoker for ≤ 15 years | 236 (49.9%) |

Current reformed smoker for > 15 years | 81 (17.1%) |

Current reformed smoker, duration not specified | 5 (1.1%) |

Current smoker | 133 (28.1%) |

Lifelong non-smoker | 18 (3.8%) |

Lymph Node Metastasis | |

N0 | 302 (63.8%) |

N1, N2, N3 | 165 (34.9%) |

NX | 6 (1.3%) |

Distant Metastasis | |

M0 | 386 (81.6%) |

M1, M1a, M1b | 7 (1.5%) |

MX | 80 (16.9%) |

Pathological Stage | |

I | 236 (49.9%) |

II | 150 (31.7%) |

III | 80 (16.9%) |

IV | 7 (1.5%) |

**Table 2.**Genes selected by the four competing models. A risk gene with a positive coefficient from the fitted PenCox model is denoted by “+”, while a protective gene with a negative coefficient is denoted by “−”.

Model (No. of Genes Selected) | Gene Names |
---|---|

Naive + PenCox (6) | PCDHA5(+), C9ORF131(+), PM20D1(+), PCDHA3(+), FAM196B(+), PITX3(−) |

CRIS + PenCox (10) | CCDC79(+), LCN1(+), GPR78(+), SSX1(+), CCKAR(+), SLC10A2(+), STARD6(−), GUCY2F(−), DPPA2(+), LINC00628(+) |

IPOD + PenCox (4) | TRIM58(+), C9ORF131(+), PKNOX2(+), PCDHGA11(+) |

ESIS + PenCox (6) | NACC2(+), FAM65A(+), LOC641845(−), MON1B(+), IBTK(+), SDHAF3(−) |

**Table 3.**Multivariable Cox regression analysis of the risk of death against the 6-gene signature identified by ESIS+PenCox and other clinical covariates. CI denotes confidence interval.

Variable | Hazard Ratio (95% CI) | p-Value |
---|---|---|

6-gene signature | 12.59 (4.11, 38.56) | <0.001 |

Age | 1.02 (1.01, 1.04) | 0.008 |

Gender | ||

Male | 0.92 (0.67, 1.28) | 0.629 |

Female | - | - |

Tumor stage | ||

I | 0.59 (0.42, 0.83) | 0.003 |

II | 0.63 (0.43, 0.92) | 0.018 |

III or IV | - | - |

Smoking history | ||

Lifelong non-smoker | 1.94 (0.83, 4.54) | 0.126 |

Current smoker | 1.54 (1.14, 2.07) | 0.005 |

Current reformed smoker | - | - |

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

## Share and Cite

**MDPI and ACS Style**

Ke, C.; Bandyopadhyay, D.; Acunzo, M.; Winn, R.
Gene Screening in High-Throughput Right-Censored Lung Cancer Data. *Onco* **2022**, *2*, 305-318.
https://doi.org/10.3390/onco2040017

**AMA Style**

Ke C, Bandyopadhyay D, Acunzo M, Winn R.
Gene Screening in High-Throughput Right-Censored Lung Cancer Data. *Onco*. 2022; 2(4):305-318.
https://doi.org/10.3390/onco2040017

**Chicago/Turabian Style**

Ke, Chenlu, Dipankar Bandyopadhyay, Mario Acunzo, and Robert Winn.
2022. "Gene Screening in High-Throughput Right-Censored Lung Cancer Data" *Onco* 2, no. 4: 305-318.
https://doi.org/10.3390/onco2040017